A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors

Clinical trial NCT03965845 · COMPLETED

Trial details

NCT number: NCT03965845
Sponsor: Calithera Biosciences, Inc
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Solid Tumors NSCLC CRC KRAS Gene Mutation

Start date: 2019-06-25
Primary completion: 2021-09-24
Enrollment: 53

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.